We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
- Authors
Roach, M, 3rd; DeSilvio, M; Lawton, C; Uhl, V; Machtay, M; Seider, M J; Rotman, M; Jones, C; Asbell, S O; Valicenti, R K; Han, S; Thomas, C R, Jr; Shipley, W S; Radiation Therapy Oncology Group 9413
- Abstract
This trial tested the hypothesis that combined androgen suppression (CAS) and whole-pelvic (WP) radiotherapy (RT) followed by a boost to the prostate improves progression-free survival (PFS) by 10% compared with CAS and prostate-only (PO) RT. This trial also tested the hypothesis that neoadjuvant and concurrent hormonal therapy (NCHT) improves PFS compared with adjuvant hormonal therapy (AHT) by 10%.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Vol 21, Issue 10, p1904
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2003.05.004